MaaT013
- Generic Name
- MaaT013
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT04988841
- Locations
- 🇫🇷
Hôpital Nantes Hôtel Dieu, Nantes, France
🇫🇷Hôpital Saint Louis, Paris, France
🇫🇷Hôpital Gustave Roussy, Villejuif, France
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- MaaT Pharma
- Target Recruit Count
- 66
- Registration Number
- NCT04769895
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇫🇷CHRU Lille - Hopital Claude Huriez, Lille, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- MaaT Pharma
- Registration Number
- NCT04768907
- Locations
- 🇫🇷
Chu Rouen, Rouen, France
🇫🇷Institut de Cancerologie de Strabsourg, Strasbourg, France
🇫🇷Chu Angers, Angers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath